ANTENGENE CORP. DL-0001 (722) - Net Assets
Based on the latest financial reports, ANTENGENE CORP. DL-0001 (722) has net assets worth €642.43 Million EUR (≈ $751.07 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€1.26 Billion ≈ $1.47 Billion USD) and total liabilities (€614.60 Million ≈ $718.53 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 722 financial resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €642.43 Million |
| % of Total Assets | 51.11% |
| Annual Growth Rate | -28.03% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 3.26 |
ANTENGENE CORP. DL-0001 - Net Assets Trend (2021–2025)
This chart illustrates how ANTENGENE CORP. DL-0001's net assets have evolved over time, based on quarterly financial data. Also explore total assets of ANTENGENE CORP. DL-0001 for the complete picture of this company's asset base.
Annual Net Assets for ANTENGENE CORP. DL-0001 (2021–2025)
The table below shows the annual net assets of ANTENGENE CORP. DL-0001 from 2021 to 2025. For live valuation and market cap data, see ANTENGENE CORP. DL-0001 (722) total market value.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €642.43 Million ≈ $751.07 Million |
-24.49% |
| 2024-12-31 | €850.80 Million ≈ $994.68 Million |
-25.85% |
| 2023-12-31 | €1.15 Billion ≈ $1.34 Billion |
-33.03% |
| 2022-12-31 | €1.71 Billion ≈ $2.00 Billion |
-28.44% |
| 2021-12-31 | €2.39 Billion ≈ $2.80 Billion |
-- |
Equity Component Analysis
This analysis shows how different components contribute to ANTENGENE CORP. DL-0001's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 174105100000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €6.47 Billion | 1007.75% |
| Total Equity | €642.43 Million | 100.00% |
ANTENGENE CORP. DL-0001 Competitors by Market Cap
The table below lists competitors of ANTENGENE CORP. DL-0001 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Drugs Made In America Acquisition Corp. Units
NASDAQ:DMAAU
|
$308.64 Million |
|
Republic Digital Acquisition Company Class A Ordinary Shares
NASDAQ:RDAG
|
$308.70 Million |
|
Argo Global Listed Infrastructure Ltd
AU:ALI
|
$308.70 Million |
|
Simulations Plus Inc
NASDAQ:SLP
|
$308.74 Million |
|
Y.U.D. Yangtze River Investment Industry Co Ltd
SHG:600119
|
$308.41 Million |
|
Shanghai Aiyingshi Co Ltd
SHG:603214
|
$308.35 Million |
|
Is Finansal Kiralama AS
IS:ISFIN
|
$308.35 Million |
|
Samyang Holdings
KO:000070
|
$308.29 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in ANTENGENE CORP. DL-0001's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 850,801,000 to 642,429,000, a change of -208,372,000 (-24.5%).
- Net loss of 239,130,000 reduced equity.
- Share repurchases of 1,389,000 reduced equity.
- New share issuances of 129,000 increased equity.
- Other factors increased equity by 32,018,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-239.13 Million | -37.22% |
| Share Repurchases | €1.39 Million | -0.22% |
| Share Issuances | €129.00K | +0.02% |
| Other Changes | €32.02 Million | +4.98% |
| Total Change | €- | -24.49% |
Book Value vs Market Value Analysis
This analysis compares ANTENGENE CORP. DL-0001's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.44x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has increased from 0.12x to 0.44x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €3.85 | €0.46 | x |
| 2022-12-31 | €2.80 | €0.46 | x |
| 2023-12-31 | €1.88 | €0.46 | x |
| 2024-12-31 | €1.39 | €0.46 | x |
| 2025-12-31 | €1.05 | €0.46 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently ANTENGENE CORP. DL-0001 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -37.22%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -227.01%
- • Asset Turnover: 0.08x
- • Equity Multiplier: 1.96x
- Recent ROE (-37.22%) is above the historical average (-37.58%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -27.38% | -2278.60% | 0.01x | 1.07x | €-894.96 Million |
| 2022 | -35.11% | -375.61% | 0.07x | 1.25x | €-772.82 Million |
| 2023 | -50.65% | -863.51% | 0.04x | 1.41x | €-695.92 Million |
| 2024 | -37.52% | -347.20% | 0.07x | 1.58x | €-404.33 Million |
| 2025 | -37.22% | -227.01% | 0.08x | 1.96x | €-303.37 Million |
Industry Comparison
This section compares ANTENGENE CORP. DL-0001's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $353,958,690
- Average return on equity (ROE) among peers: -34.11%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| ANTENGENE CORP. DL-0001 (722) | €642.43 Million | -27.38% | 0.96x | $308.52 Million |
| PROQR THERAPEUTICS EO-04 (0PQ) | $88.56 Million | -31.35% | 0.90x | $142.34 Million |
| TIZIANA LIFE SCIENCES LTD (0RP) | $19.57 Million | -78.67% | 0.35x | $161.62 Million |
| Theravance Biopharma Inc (0TB) | $289.79 Million | -81.80% | 0.17x | $823.46 Million |
| I-MAB SPONS.ADS/1 -0001 (0VY) | $201.16 Million | -11.05% | 0.06x | $204.16 Million |
| PreveCeutical Medical Inc (18H) | $-4.49 Million | 0.00% | 0.00x | $3.34 Million |
| Argen-X (1AE) | $1.36 Billion | -38.77% | 0.36x | $41.67 Billion |
| WAVE LIFE SCIENCES LTD. (1U5) | $518.36 Million | -39.43% | 0.23x | $1.14 Billion |
| BIOCURE TECHNOLOGY INC. (1WH) | $-852.32K | 0.00% | 0.00x | $960.84K |
| ZAI LAB LTD0000006 (1ZLB) | $796.12 Million | -42.03% | 0.30x | $1.82 Billion |
| BioNTech SE (22UA) | $267.00 Million | -17.98% | 1.45x | $20.05 Billion |
About ANTENGENE CORP. DL-0001
Antengene Corporation Limited, a clinical-stage APAC biopharmaceutical company, develops novel oncology therapies in Greater China and internationally. The company's commercialized assets include ATG-010 (selinexor), an oral SINE compound for the treatment of various hematological malignancies and solid tumors comprising relapsed/refractory multiple myeloma (rrMM), relapsed/refractory diffuse lar… Read more